Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study ...
Abstract Background In 2018, meningococcal ACWY-TT vaccine (MenACWY-TT) was offered to adolescents in the Netherlands within the National Immunization Programme at 14 years of age. A questionnaire study assessed the tolerability of this vaccine. Methods Five thousand adolescents were invited to participate and to fill in two questionnaires about systemic events in the week before vaccination and local reactions and systemic events in the week after vaccination. Frequencies of local and systemic adverse events in the week after vaccination were calculated. Association between the occurrence of... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Datenquelle |
Erscheinungsdatum: | 2021 |
Verlag/Hrsg.: |
figshare
|
Schlagwörter: | Medicine / Biotechnology / Immunology / FOS: Clinical medicine / 69999 Biological Sciences not elsewhere classified / FOS: Biological sciences / Cancer / Science Policy |
Sprache: | unknown |
Permalink: | https://search.fid-benelux.de/Record/base-29167512 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://dx.doi.org/10.6084/m9.figshare.c.5634771.v1 |
Abstract Background In 2018, meningococcal ACWY-TT vaccine (MenACWY-TT) was offered to adolescents in the Netherlands within the National Immunization Programme at 14 years of age. A questionnaire study assessed the tolerability of this vaccine. Methods Five thousand adolescents were invited to participate and to fill in two questionnaires about systemic events in the week before vaccination and local reactions and systemic events in the week after vaccination. Frequencies of local and systemic adverse events in the week after vaccination were calculated. Association between the occurrence of systemic symptoms in the week before and after the vaccination was tested by using generalized mixed models (GLMM). Results Of all adolescents, 139 returned one or both questionnaires. Any local reaction within 7 days after vaccination was reported by 55.6% of the adolescents. Pain (50%) and reduced use of the injected arm (21.3%) were most often reported. Any systemic event was reported by 67.6% of the participants, ...